|
|
Interstitial
chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data
Boiardi A, Salmaggi A, Pozzi A, Broggi G, Silvani A
Department of Neurology, Istituto Nazionale Neurologico Carlo
Besta, Milano, Italy.
We undertook a phase I-II
trail of loco-regional mitoxantrone in 12 patients affected by malignant
gliomas.
Mitoxantrone was delivered at tumor recurrence by Ommaya reservoir, with 2
cycles and a 1 month interval between each cycle, in conjunction with systemic
chemotherapy (8 pts) or not (4 pts).
Treatment tolerability was good, and 9 of the patients showed either response or
stable disease at the end of the treatment schedule.
Regardless of associated chemotherapy, time to further tumor progression was at
6 months.
A combination of early systemic and loco-regional chemotherapy with surgery and
radiotherapy seems worth while pursuing in the therapeutic approach to malignant
gliomas.
PMID: 8699238 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8699238&dopt=Abstract
|
